| Company Name: |
Suzhou Rovathin Foreign Trade Co.,Ltd
|
| Tel: |
0512-65816829 18662214788 |
| Email: |
info@rovathin.com.cn |
| Products Intro: |
Product Name:N-(3-(5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,6-difluorophenyl)propane-1-sulfonamide CAS:2409140-12-9 Package:100g/;1kg/
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Email: |
doncunbiosci@gmail.com |
| Products Intro: |
Product Name:HRX-0233 Purity:98% HPLC Package:100mg,250mg,1g
|
| Company Name: |
Changzhou Borl Biotechnology Co.,LTD
|
| Tel: |
13606124132;13656121842 |
| Email: |
luyan0021@163.com |
| Products Intro: |
Product Name:N-(3-(5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,6-difluorophenyl)propane-1-sulfonamide CAS:2409140-12-9 Purity:98% Package:1g
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:HRX-0233 CAS:2409140-12-9 Package:50mg/RMB 21300
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Email: |
info@biorbyt.com |
| Products Intro: |
Product Name:HRX-0233 CAS:2409140-12-9
|
|
| | N-(3-(5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,6-difluorophenyl)propane-1-sulfonamide Basic information |
| | N-(3-(5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,6-difluorophenyl)propane-1-sulfonamide Chemical Properties |
| density | 1.485±0.06 g/cm3(Predicted) | | pka | 6.43±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | N-(3-(5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,6-difluorophenyl)propane-1-sulfonamide Usage And Synthesis |
| Uses | HRX-0233 is a small-molecule MAP2K4 inhibitor. HRX-0233 results in strong tumor shrinkage without any apparent toxicity in H358 KRASG12C-mutant non-small cell lung cancers (NSCLC) in vivo. HRX-0233 efficiently prevents feedback activation of receptor tyrosine kinases (RTKs) upon monotherapy KRAS inhibitor Sotorasib (HY-114277) and causes a more sustained and complete inhibition of MAPK signaling. HRX-0233 is promising for research of AR-negative prostate cancer, lung and colon cancers[1][2]. | | References | [1] Jansen RA, et al. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers. Proc Natl Acad Sci U S A. 2024 Feb 27;121(9):e2319492121. DOI:10.1073/pnas.2319492121 [2] Tipayasri P. Development of Rational Combination Therapies for Patients with Metastatic Prostate Cancer and Loss of the PTEN Tumor Suppressor Gene[D]. , 2024. |
| | N-(3-(5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,6-difluorophenyl)propane-1-sulfonamide Preparation Products And Raw materials |
|